- The
company aims to promote healthier administration methods, eliminating the
need for sweeteners to mask taste
- Lexaria’s
mission is to save lives with its technology, which allows for delivery of
drug molecules through ingestible means
- The
company is seeing high demand in North American markets for DehydraTECH in
cannabis-infused beverages
- Lexaria
recently announced its entry into a CBD-beverage formulation license
agreement with a Nevada-based company
Traditionally, consumers have relied on smoking to achieve
higher absorption rates and fast onset of bioactive compounds such as nicotine
and cannabinoids. Ingesting drugs and molecules through edibles is simply safer
than inhaling them. However, the absorption of edibles has proven slow, and the
taste can be unpleasant without the aid of sweeteners.
Now, thanks to a revolutionary oral technology, it is
possible to deliver bioactive substances via oral ingestion without the need
for the unhealthy practices of inhalational or added sweeteners.
Biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has
developed and out-licenses its drug-delivery platform, DehydraTECH, promoting
healthier administration methods. This revolutionary oral technology increases
the product’s absorption rate, reduces the time of onset and masks the
undesirable taste, thus eliminating the need for sweeteners in edibles. The
overall dosing is lowered, and the effectiveness of ingestible drugs and other
beneficial molecules is increased. The technology offers the consumer the
benefits of ingestion without the related risks that come with smoking.
“Lexaria Bioscience has the actual opportunity of changing
the world,” LXRP CEO Chris Bunka noted on CEO Clipsvia
YouTube (http://ibn.fm/cQqEd).
“We can do it through saving lives, making health improvements for any number
of people who are ingesting any number of drugs or molecules like pain relief,
cannabinoids or nicotine. Everybody knows that smoking is not healthy. Our
technology allows for the delivery of drug molecules like cannabinoids or
nicotine through ingestible means, things that you swallow. It could be a pill,
a syrup or a cup of coffee. That technology, which is called DehydraTECH, is
optimized to carry that drug across the intestinal wall and get more of it into
your bloodstream more quickly than it otherwise could.”
Lexaria is the only company worldwide with a patent issued
for oral delivery of all cannabinoids. The company currently has 10 patents
granted for its cost-effective DehydraTECH, with 53 patent applications filed
and pending in more than 40 countries worldwide. Lexaria is anticipating
additional patents in the coming years as its intellectual property portfolio
continues to grow. By out-licensing DehydraTECH, the company anticipates a
steady stream of royalties from start-ups, as well as a Fortune 100 company.
Lexaria continues to see high demand in the North American
markets for use of DehydraTECH in beverages. The cannabis-infused and CBD
beverage markets in the United States are exploding. According to an article
from Business Insider (http://ibn.fm/1EROT), the industry could reach $600 million
in the United States by 2022, outpacing other cannabis products by more than
two times.
Lexaria Hemp Corp., a subsidiary of LXRP, recently announced
that it has entered into a definitive five-year agreement with a Nevada-based
company to provide the patented DehydraTECH for use in certain CBD-based
beverages (http://ibn.fm/FlDSU).
These beverages are expected to be produced and sold across the United States.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
